Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second‐line pembrolizumab in patients with non‐small‐cell lung cancer

by Petrova, M. P., Donev, I. S., Radanova, M. A., Eneva, M. I., Dimitrova, E. G., Valchev, G. N., Minchev, V. T., Taushanova, M. S., Boneva, M. V., Karanikolova, T. S., Gencheva, R. B., Zhbantov, G. A., Ivanova, A. I., Timcheva, C. V., P.Pavlov, B., Megdanova, V. G., Robev, B. S., Conev, N. V.
Published in Clin Exp Immunol (2020)